
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is seeing strong potential in its drug candidate VTAMA (tapinarof), which is in its commercial stage and is expected to differentiate itself from competitors due to its once-per-day dosing and favorable tolerability. With other drug candidates in different stages of development and a strong Phase Ib hemodynamic profile for mosliciguat, Roivant shows a promising outlook for future revenue growth. The company reported total revenue of $2.5M in 4Q26 and has a strong cash runway of $4.3B expected to carry it into profitability. However, risks to consider for the company include regulatory and clinical uncertainties as well as potential competition in the biopharmaceutical market.
Bears say
Roivant Sciences is likely to struggle in the future due to a lack of major developments and progress in its current drug candidates, with its flagship drug VTAMA (tapinarof) being the only one in its commercial stage. There is also increasing competition in the biopharmaceutical industry, with other companies developing similar treatments. Additionally, Roivant's financials may be hindered by the significant amount of capital needed for clinical trials and drug development.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares